Cargando…
Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
Immune Checkpoint Inhibitor (ICI) therapy has revolutionized treatment for advanced melanoma; however, only a subset of patients benefit from this treatment. Despite considerable efforts, the Tumor Mutation Burden (TMB) is the only FDA-approved biomarker in melanoma. However, the mechanisms underlyi...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485158/ https://www.ncbi.nlm.nih.gov/pubmed/36123351 http://dx.doi.org/10.1038/s41467-022-32838-4 |